COVID-19 Impacts: Biosimilar Monoclonal Antibodies (mAbs) Market will Accelerate at a CAGR of over 30% through 2020-2024|Increase in Prevalence of Chronic Diseases to Boost Growth| Technavio

Technavio has been monitoring the biosimilar monoclonal antibodies (mAbs) market and it is poised to grow by USD 8.65 billion during 2020-2024, progressing at a CAGR of over 30% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

• What was the value of the biosimilar monoclonal antibodies (mAbs) market in 2019?
• Technavio says that the value of the market was USD 3.16 billion in 2019 and is projected to reach USD 11.81 billion by 2024.

• At what rate is the market projected to grow during the forecast period 2020-2024?
• Growing at a CAGR of over 30%, the market growth will accelerate during the forecast period.

• What is the key factor driving the market?
• An increase in the prevalence of chronic diseases and the growing approval for biosimilar mAbs are the key factors driving the market growth.

• Who are the top players in the market?
• Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, and Pfizer Inc. are some of the major market participants.

• Which region is expected to hold the highest market share?
• North America

The market is concentrated, and the degree of concentration will accelerate during the forecast period. Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, and Pfizer Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

An increase in the prevalence of chronic diseases has been instrumental in driving the growth of the market.

Biosimilar monoclonal antibodies (mAbs) Market 2020-2024: Segmentation

Biosimilar monoclonal antibodies (mAbs) Market is segmented as below:

• Application
  • Cancer
  • Non-cancer
• Region
  • North America
  • Europe
  • Asia
  • ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41616

Biosimilar monoclonal antibodies (mAbs) Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our biosimilar monoclonal antibodies (mAbs) market report covers the following areas:

• Biosimilar monoclonal antibodies (mAbs) Market size
• Biosimilar monoclonal antibodies (mAbs) Market trends
• Biosimilar monoclonal antibodies (mAbs) Market analysis

This study identifies growing approval for biosimilar mAbs as one of the prime reasons driving the biosimilar monoclonal antibodies (mAbs) market growth during the next few years.

Biosimilar monoclonal antibodies (mAbs) Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the biosimilar monoclonal antibodies (mAbs) market, including some of the vendors such as Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, and Pfizer Inc. Backed with competitive intelligence and benchmarking, our research reports on the biosimilar monoclonal antibodies (mAbs) market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Biosimilar monoclonal antibodies (mAbs) Market 2020-2024: Key Highlights

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will assist biosimilar monoclonal antibodies (mAbs) market growth during the next five years
• Estimation of the biosimilar monoclonal antibodies (mAbs) market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the biosimilar monoclonal antibodies (mAbs) market
• Analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of biosimilar monoclonal antibodies (mAbs) market vendors

Table of Contents:

Executive Summary

• Market Overview

Market Landscape

• Market ecosystem
• Value chain analysis

Market Sizing

• Market definition
• Market segment analysis
• Market size 2019
• Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

Market Segmentation by Application

• Market segments
• Comparison by Application placement
• Cancer - Market size and forecast 2019-2024
• Non-cancer - Market size and forecast 2019-2024
• Market opportunity by Application

Customer Landscape

• Overview

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2019-2024
• Europe - Market size and forecast 2019-2024
• Asia - Market size and forecast 2019-2024
• ROW - Market size and forecast 2019-2024
• Key leading countries
• Market opportunity by geography

Drivers, Challenges, and Trends

• Market drivers
• Volume driver - Demand led growth
• Volume driver - Supply led growth
• Volume driver - External factors
• Volume driver - Demand shift in adjacent markets
• Price driver - Inflation
• Price driver - Shift from lower to higher priced units
• Market challenges
• Market trends

Vendor Landscape

• Overview
• Landscape disruption

Vendor Analysis

• Vendors covered
• Market positioning of vendors
• Amgen Inc.
• BIOCAD
• Biocon Ltd.
• BioXpress Therapeutics SA
• Boehringer Ingelheim International GmbH
• Celltrion Inc.
• Coherus BioSciences Inc.
• Intas Pharmaceuticals Ltd.
• Novartis AG
• Pfizer Inc.

Appendix

• Scope of the report
• Currency conversion rates for US$
• Research methodology
• List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.